Your browser doesn't support javascript.
loading
Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes.
Park, Ji Young; Rha, Seung-Woon; Choi, ByoungGeol; Choi, Jae Woong; Ryu, Sung Kee; Kim, Seunghwan; Noh, Yung-Kyun; Choi, Se Yeon; Akkala, Raghavender Goud; Li, Hu; Ali, Jabar; Xu, Shaopeng; Ngow, Harris Abdullah; Lee, Jae Joong; Lee, Gwang No; Kim, JiBak; Lee, Sunki; Na, Jin Oh; Choi, Cheol Ung; Lim, Hong Euy; Kim, Jin Won; Kim, EungJu; Park, Chang Gyu; SeogSeo, Hong; Oh, Dong Joo.
Afiliación
  • Park JY; Department of Cardiology, Eulji General Hospital, Eulji University, Seoul, Republic of Korea.
  • Rha SW; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea. Electronic address: swrha617@yahoo.co.kr.
  • Choi B; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Choi JW; Department of Cardiology, Eulji General Hospital, Eulji University, Seoul, Republic of Korea.
  • Ryu SK; Department of Cardiology, Eulji General Hospital, Eulji University, Seoul, Republic of Korea.
  • Kim S; Department of Cardiology, Eulji General Hospital, Eulji University, Seoul, Republic of Korea.
  • Noh YK; Department of Computer Science, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
  • Choi SY; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Akkala RG; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Li H; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Ali J; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Xu S; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Ngow HA; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Lee JJ; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Lee GN; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Kim J; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Lee S; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Na JO; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Choi CU; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Lim HE; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Kim JW; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Kim E; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Park CG; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • SeogSeo H; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Oh DJ; Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
Int J Cardiol ; 184: 502-506, 2015 Apr 01.
Article en En | MEDLINE | ID: mdl-25756579
ABSTRACT

BACKGROUND:

High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10mg or 20mg) on the development of NODM up to three years in Asian patients.

METHODS:

From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM (C-statistics 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n=409 patients) were enrolled for analysis.

RESULTS:

Before PSM, the cumulative incidence of NODM (5.8% vs. 2.1%, p<0.001), myocardial infarction (0.5% vs. 0.1%, p-value=0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value=0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p=0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value=1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR 1.99, 95% CI 1.00-3.98, p-value 0.050).

CONCLUSIONS:

In this study, the use of LDA tended to be a risk factor for NODM in Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus / Dislipidemias / Atorvastatina Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Int J Cardiol Año: 2015 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus / Dislipidemias / Atorvastatina Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Asia Idioma: En Revista: Int J Cardiol Año: 2015 Tipo del documento: Article